Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Brain Tumor : Recurrent or refractory medulloblastoma
Subjects taking part in this research study have a type of brain tumor called medulloblastoma that is growing or has come back (recurred). Because there has been a major challenge in finding an effective treatment that these tumors will respond to, this study is testing GDC-0449 given once daily based on data available on the recently conducted Phase I study. We are using GDC-0449 because it seems to block a gene that is thought to be involved in the development of brain tumors.
This Phase II study has been designed to demonstrate the clinical benefit of GDC-0449 in children with recurrent medulloblastoma. This study will seek to describe the efficacy, response and side effects of the drug in patients with recurrent or refractory medulloblastoma.
For current eligibility status of this clinical study, referring physician and patient’s family may contact St. Jude’s Brain Tumor Team at (901) 595-2544 or (901) 595-4599.
Amar Gajjar, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: 901-595-2544 or 901-595-4599
Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Contact us by email anytime, 24 hours a day, 7 days a week.
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.